DDInter907 DDInter927
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Iloperidone {u} (Compound) resembles {v} (Compound) Gefitinib
Iloperidone {u} may lead to a major life threatening interaction when taken with {v} Cisapride
Iloperidone {u} (Compound) resembles {v} (Compound) Paliperidone
Iloperidone {u} (Compound) binds {v} (Gene) DRD1
Iloperidone {u} (Compound) upregulates {v} (Gene) PAK6
Iloperidone {u} (Compound) downregulates {v} (Gene) DKK3
Iloperidone {u} (Compound) causes {v} (Side Effect) Menstruation irregular
Iloperidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Iloperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Iloperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clidinium
Iloperidone (Compound) resembles Gefitinib (Compound)
Iloperidone may lead to a major life threatening interaction when taken with Cisapride
Iloperidone (Compound) resembles Paliperidone (Compound)
Iloperidone (Compound) binds DRD1 (Gene)
Iloperidone (Compound) upregulates PAK6 (Gene)
Iloperidone (Compound) downregulates DKK3 (Gene)
Iloperidone (Compound) causes Menstruation irregular (Side Effect)
Iloperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Clidinium